Pharma Reconciliation Insights

API Imports: Customs Tariff Act 1975 Reconciliation for Formulators

A Tier-1 integrated pharma formulator running a Halol formulation plant sourcing Amoxicillin trihydrate under HSN 2941.10 ex-Shanghai must reconcile Bill of Entry level Basic Customs Duty at 7.5 percent, Agriculture Infrastructure and Development Cess at 5 percent, IGST at 5 percent on assessable value, ICEGATE e-payment challan, freight forwarder invoice against the BoE, supplier commercial invoice with Ind AS 21 foreign exchange translation, and monthly IGST-import ITC availment against Table 4 of GSTR-3B.

API CDMO Margin Reconciliation: Cost-Plus, Fixed-Price, Milestone

A Tier-2 CRAMS operator running a ~Rs 650 crore per year CDMO contract book — illustratively split ~40 percent cost-plus at ~18 percent average margin, ~35 percent fixed-price at ~32 percent average margin, and ~25 percent milestone at ~28 percent average margin — must run a contract-wise revenue-recognition tracker under Ind AS 115 with the method appropriate to each contract type, a per-contract-type margin variance table at monthly close, a Section 92BA Specified Domestic Transaction flag on every intra-group contract, and a Section 194Q payment code 1031 TDS credit register per principal against Form 26AS.

API Yield Loss and Solvent Recovery: Reconciling the Weight-Loss Gap

An illustrative Hyderabad-based Chapter 29 API custom-synthesis unit runs a 4-step synthesis at a theoretical mole-balance yield of 72 percent and an actual isolated yield of 65 percent — a 7 percentage-point yield gap that must be reconciled batch by batch against mother-liquor loss, wash-cycle loss, and filtration-and-drying loss. The parallel hexane recovery cycle at 87 percent recovery leaves a 13 percent make-up solvent requirement per batch — where the make-up hexane sits at HSN 2710 with the Notification 09/2022 refund block on the Chapter 27 leg still in force under Section 54(3) of the CGST Act 2017.

Backward Integration: API Transfer Pricing to Formulation Plants

A backward-integrated Tier-1 pharma group transferring Chapter 29 antibiotic APIs intra-group from a Maharashtra API plant to a Goa formulation plant at an aggregate annual volume of the order of Rs 350 crore crosses the Rs 20 crore Section 92BA threshold and triggers Rule 10D three-tier transfer pricing documentation. The reconciliation surface spans the intra-group invoice register, the arm's length benchmarking study, the Form 3CEB filing with the annual return, and the GST Section 15 read with Rule 28 related-party valuation continuity from IGST 5 percent Chapter 29 dispatch to ITC availment at the formulation plant.

Clinical Trials and CRO Fees: What Section 35(2AB) Allows

A Tier-1 Indian innovator pharma company running a DSIR-approved R&D innovation centre commissions clinical CROs for Phase 2 and Phase 3 trials at aggregate outsourced fees of the order of Rs 60 crore per molecule programme. The Section 35(2AB) reconciliation surface is the carve-out between clinical trial expenditure operating under contract linked to the DSIR facility (eligible for the 100 percent weighted deduction) and regulatory strategy consulting (non-eligible for Section 35(2AB) but deductible under Section 37 wholly-and-exclusively) — with Form 3CL year-end certification, Section 195 or Section 194J TDS treatment, and Ind AS 21 forex retranslation reconciled per CRO invoice.

DSIR Form 3CL / 3CLA: Approval Trail and Year-End Reconciliation

A pharma R&D unit approved by DSIR under Form 3CM must, at year-end, run a full reconciliation cascade from its scientific R&D cost-centre general ledger through the DSIR-listed items eligibility filter to the Form 3CL CA quantum certification and the Form 3CLA return-of-income schedule — with the Section 35(2AB) weighted deduction now at 100 percent (down from 150 percent till FY 2019-20 and 200 percent till FY 2016-17) and the book-tax gap under Ind AS 38 development-phase capitalisation creating deferred tax under Ind AS 12.

Ind AS 38 vs Section 35(2AB): Reconciling Book vs Tax R&D Treatment

An illustrative Tier-2 biosimilars persona running a Bangalore DSIR-approved R&D facility incurs FY 2026-27 R&D spend of the order of Rs 320 crore — Rs 145 crore research-phase and Rs 175 crore development-phase. Ind AS 38 capitalises the development phase on the balance sheet once the six-condition test is met; Section 35(2AB) IT Act 2025 revenue-expenses the entire eligible spend at the DSIR facility for a 100 percent weighted deduction. The book-tax gap is Rs 175 crore in FY 2026-27, generating an illustrative Rs 44 crore deferred tax asset under Ind AS 12 that unwinds over the intangible amortisation period once the biosimilar launches.

Chapter 27 Solvents Blocked: Notification 09/2022 for Pharma Refund Teams

CBIC Notification 09/2022-Central Tax (Rate) dated 13 July 2022, effective 18 July 2022, invokes clause (ii) of the first proviso to Section 54(3) to bar refund of unutilised ITC where the output supplies fall under HSN Chapter 27 — the chapter that houses hexane, isopropyl alcohol, methanol, toluene and methyl ethyl ketone. For an India API-centric manufacturer running a Chapter 29 output at 5 percent GST against a solvent input base at 18 percent GST, the segregation discipline in the monthly Form GST RFD-01 refund workbook — Chapter 27 solvent ITC held in a distinct blocked-refund bucket, working-capital lock-up modelled at Rs 40 to 55 crore per year per major refiner — is what separates a defensible refund position from a Section 74 penalty exposure.

Notification 14/2022: How Net-ITC Reshaped Pharma Refund Math

Notification 14/2022-Central Tax dated 5 July 2022 amended Rule 89(5) of the CGST Rules 2017 prospectively — refund applications filed on or after that date apply an amended Net ITC formula that excludes input services and capital goods. For a Tier-1 pharma API unit at Ankleshwar filing quarterly Section 54(3) refunds against inverted-duty accumulation, the amendment produced a Rs 3 to 4 crore per quarter permanent recurring reduction in refund quantum against pre-amendment claims — recoverable only through disciplined per-invoice input classification and a Net-ITC composition workbook that separates goods, services and capital goods at source.

The 5/12/18 Input Mix: A Worked Refund Example for Pharma Formulations

For an illustrative Tier-1 Chapter 30 formulator's Baddi plant producing about Rs 55 crore of monthly formulation output at 5 percent GST post-22-September-2025, the 5/12/18 input mix — API at 5 percent, glass vials at 18 percent, printed cartons at 12 percent, excipients at 5 percent — feeds a Net ITC of the order of Rs 3.54 crore per month after carving out Chapter 27 solvent ITC under Notification 09/2022 and excluding input services and capital-goods ITC under Notification 14/2022. This walkthrough builds the line-by-line input register, the Net ITC composition workbook, and the Rule 89(5) maximum-refund computation the finance team files in Form GST RFD-01.

Section 54(3) RFD-01 for Pharma: The End-to-End Filing Workflow

A Tier-1 Hyderabad plant closing August 2026 books under the post-22-September-2025 rate regime runs a fifteen-step monthly RFD-01 workflow — from GSTR-3B Table 4 and Table 3.1 tie-out through Rule 89(5) computation to Section 54(6) provisional refund tracking against an illustrative maximum refund of Rs 6.4 crore on a Rs 42 crore Chapter 30 output month.

USFDA Warning Letters: Ind AS 37 Provisions and Contingent Liabilities

A USFDA warning letter is the trigger event that converts a plant-level compliance risk into a formal Ind AS 37 accounting question. The finance team applies the three-limb recognition test — present obligation, probable outflow, reliable estimate — measures the provision at best estimate under para 36, builds a movement schedule under para 84, splits the revex from the capex leg, and reconciles the book-tax gap against Section 37 IT Act's payment-basis deduction.

API vs Formulation: HSN 2941 / 3003 / 3004 Reconciliation Guide

A backward-integrated pharma group running an API manufacturing unit that dispatches Amoxicillin trihydrate and Cefixime under HSN 2941 to a sister formulation plant that converts the bulk drug to HSN 3004 finished dosage forms must reconcile the material-flow register, the inter-unit invoice, the Section 92BA arm's-length documentation, the Chapter-27 solvent exclusion under Notification 09/2022 for Rule 89(5) refund at the API side, and the Section 194Q buyer-side TDS on the cross-plant procurement.

GST 2.0 for Pharma: The 56th Council Drug and Device Reset

The 56th GST Council meeting held 3 September 2025 with effective date 22 September 2025 collapsed the pharmaceutical rate structure — all drugs to 5 percent, life-saving oncology and HIV and TB and rare-disease schedules to nil rate, medical devices under HSN 9018 to 9022 from 18 percent to 5 percent. The pivot rewrites every rate table across an integrated Indian formulator's API-plus-formulation-plus-device portfolio, deepens the Rule 89(5) inverted-duty refund cycle for the 18 percent packaging inputs, keeps Chapter 27 solvents permanently blocked under Notification 09/2022-Central Tax (Rate), and introduces Rule 42 and Rule 43 common-credit reversal exposure on the nil-rated life-saving sub-portfolio.

Reading the 56th Council FAQ: Q10, Q25, Q51 for Pharma Teams

The 56th GST Council FAQ published alongside the 3-September-2025 press release carries three questions — Q10 on the deepened pharma inversion, Q25 on the medical-device rate transition, and Q51 on the life-saving drugs nil-rate schedule — that a pharma finance controller must read as compliance instructions, not as reference commentary. Each question resolves to a specific ERP-field change, an audit-trail entry, and a monthly review cadence with the tax head and the statutory auditor as first-two-cycle observer.

How-To 14 min read

Nil-Rated Life-Saving Drugs: Cancer, HIV, TB, Rare Disease Schedule

The 56th GST Council schedule notifies specified life-saving cancer, HIV, TB, and rare-disease drugs at a nil output rate effective 22 September 2025. For the producer this is not a windfall — it is a Section 17(2) trigger that pulls the entire portfolio's common ITC on API, packaging, sterile fill-finish, labelling, and capital goods into a Rule 42 proportionate reversal and a Rule 43 60-month amortisation reversal. A biosimilar oncology franchise at Rs 1,100 crore portfolio scale can face Rs 40 to 60 crore of annual reversal exposure that must be tracked at product level, at common-credit register level, and at capital-goods amortisation level.

Loan-Licensing and Third-Party Manufacturing: The Pharma Reconciliation Guide

A Tier-1 pharma brand-owner running its Sikkim Section 80-IE unit for API and intermediate manufacture, dispatching to a Baddi third-party manufacturer under a loan-licensing arrangement for finished dosage form, must reconcile Section 143 CGST job-work dispatches within the 1-year window, Rule 45 challan-based movement without payment of tax, the ITC-04 quarterly return, third-party HSN 9988 job-work invoicing at 12 percent IGST, and the Section 43B(h) 45-day MSME payment aging cycle across the cross-state loan-licensee register.

Medical Devices at 5%: HSN 9018–9022 Rate-Change Reconciliation

The 56th GST Council rate change effective 22 September 2025 moved medical instruments and apparatus under HSN 9018 to 9022 from 18 percent GST to 5 percent. The reconciliation surfaces are SKU-wise MRP recalculation per DPCO Schedule I, pre-versus-post-22-September invoice reconciliation, Rule 89(5) monthly RFD-01 refund filing against 18 percent input GST accumulation, and Section 15(2) treatment of any post-supply MRP-transition discount.

Pharma Inventory Rate-Switch: Reconciling 12% Stock Sold at 5%

The 56th GST Council rate rationalisation of 3 September 2025, effective 22 September 2025, cut all drugs to a flat 5 percent output GST. A large formulator depot holding pre-cutover stock at 12 percent landed input tax but selling that same stock at 5 percent output post-cutover has to reconcile a stock-in-trade ITC ledger, a Section 15 valuation register, and — critically — establish on the record that no Rule 42 or Rule 43 common-credit reversal is required because the ITC on 12 percent input was validly claimed at the time of purchase.

How-To 17 min read

PLI Pharma Rs 15,000 Crore: Eligibility, Incremental Sales, Disbursement

A Category 1 PLI Pharma applicant on the DoP Rs 15,000 crore scheme must reconcile an FY 2019-20 identified-product base sales register, a Year 1 through Year 6 incremental sales bridge tested against DoP-set year thresholds, the quarterly claim workbook filed on the DoP PLI portal, and the PLI grant income accounting under Ind AS 20 with the Section 115JB Minimum Alternate Tax book-profit adjustment on the grant leg. Missing any hop breaks the disbursement cycle and delays the annual claim run against the Rs 100 crore per applicant per year Category 1 cap.

Rule 89(5) for Pharma Formulations: The Complete Refund Playbook

A Tier-1 integrated pharma formulator running Ahmedabad, Baddi, and Sikkim plants at an FY 2026-27 aggregate domestic turnover of the order of Rs 8,500 crore must build a per-plant per-month Rule 89(5) refund workbook against 5 percent Chapter 30 output, decompose Net ITC by input HSN chapter, carve out the Notification 09/2022 Chapter 27 solvent proportion, and file Form GST RFD-01 monthly against accumulated inverted-duty credit — with monthly refund quantum in the Rs 42-58 crore per major plant range depending on API-versus-solvent input mix.

Section 35(2AB) for Pharma R&D: The DSIR Reconciliation Playbook

Section 35(2AB) allows a 100 percent weighted deduction on in-house R&D revenue expenditure at a DSIR-approved facility. The reconciliation cascade runs from the R&D cost-centre general ledger through the Ind AS 38 six-condition development-phase test, through the DSIR-listed-item filter, to the Form 3CL year-end quantum certified by a chartered accountant and the Form 3CLA schedule in the income-tax return. Ind AS 12 then draws a deferred tax bridge across the timing gap between book capitalisation and tax revenue-expensed treatment.

Straddle Invoices: Pharma Movements Across the 22-Sept-2025 Cutover

A pharma formulator invoicing a distribution partner on 21-September-2025 at 12 percent for HSN 3004 formulations, with goods physically received at the distributor site on 24-September-2025, is caught in the Section 14 CGST straddle-invoice window created by the 56th GST Council flat 5 percent rate that took effect from 22-September-2025. This walkthrough covers Section 14 time-of-supply mechanics, Section 34 credit-note issuance, distributor-side ITC reversal, and the reconciliation surface that closes the 21-30 September pipeline window cleanly.

USFDA Form 483: Remediation Cost Accounting Under Section 37

An Indian pharma group receiving a USFDA Form 483 with 12 observations across data integrity, sterility assurance, and CAPA closure runs a 3-year remediation programme split roughly 55 percent revenue expenditure deductible under Section 37 and 45 percent capital expenditure capitalised under Ind AS 16. The controller must reconcile 483-observation-wise remediation cost, per-invoice Section 37 wholly-and-exclusively test evidence, Section 195 foreign remittance TDS on offshore CGMP consulting under the India-US DTAA, Section 194J code 1005 TDS on Indian sub-contractors, and an Ind AS 37 provision movement schedule from 483 acknowledgement through warning letter to close-out.

CGHS and ECHS Hospital Pharma Billing Reconciliation for Empanelled Suppliers

Empanelled CGHS and ECHS hospital pharmacies bill against rate-list pricing on the Schedule of Rates, submit monthly bills in a defined file format, and wait T+60 to T+180 for settlement minus deductions. Four deduction classes — non-formulary, rate-list mismatch, prescription compliance, beneficiary ID — eat 4-9% of gross billing before payment. Government deductors apply Section 393(1) Sl. 6(i) contractor TDS (codes 1023/1024) on the bill. Reconciliation has to tie every prescription line through dispense, claim, deduction memo and bank credit.

How-To 11 min read

GST Refund for Pharma under Inverted Duty Structure: Rule 89(5) Application

Indian pharma manufacturers buy active pharmaceutical ingredients (APIs) at 18% GST and sell formulations at 12% GST. The inverted duty structure accumulates unutilised ITC every month, refundable under Rule 89(5) CGST Rules via Form GST RFD-01, subject to a 2-year limitation, capital-goods exclusion in Net ITC, and the Circular 79/53/2018 procedural overlay. A ₹120 crore formulation manufacturer carries a ₹2.4 crore annual refund stream that must reconcile cleanly against GSTR-2B, GSTR-3B and the RFD formula at every quarter close.

Medical Representative Settlement and Expense Reconciliation in Indian Pharma

Indian pharma companies run a structurally complex MR settlement stack: fixed salary plus variable per-doctor incentive, physician sample distribution tied to Section 17(2)(vi) perquisite tax, UCPMP 2024 marketing code compliance, CSR-vs-marketing expense classification, and Section 393(1) Sl. 6(i) contractor TDS (codes 1023/1024) on contractor MR engagements. Each rail breaks differently and the per-MR ₹4-12 lakh/year cost band amplifies even small variances at scale.

Pharma Distributor and Stockist Reconciliation for Indian Pharmaceutical Manufacturers

Indian pharma manufacturers move 80-90% of revenue through a three-tier CFA → super-stockist → retail chemist distribution rail. Reconciliation must close five gaps at once: primary-vs-secondary sales (sell-in vs sell-out), CFA service-charge settlement, expiry returns split into saleable (credit-note) and non-saleable (destruction certificate), Section 393(1) Sl. 6(i) contractor TDS (codes 1023/1024) on CFA charges, and GST credit notes under Section 34 on returned stock.

Pharma Expiry Returns Reconciliation: Saleable vs Non-Saleable Accounting

Indian pharma companies absorb a structurally large expiry returns stream — 4-6% of secondary sales routinely cycle back from stockists in the six months before stamped expiry. The split between saleable (near-expiry repricing, redistribution) and non-saleable (CDSCO destruction, Schedule M GMP, batch traceability) drives every downstream entry: the Section 34 CGST credit note, the Rule 42 proportionate ITC reversal on inputs consumed in destroyed goods, the Ind AS 36 impairment provision, and the Section 393 TDS overlay on destruction-service vendors.

How-To 11 min read

Pharma R&D Tax Incentive: Section 35(2AB) Weighted Deduction and DSIR Recognition

Section 35(2AB) gave Indian pharma a 150% weighted R&D deduction until FY 2019-20, sunset to 100% from FY 2020-21 onward. The mechanic still has live cycle work: DSIR must recognise the in-house R&D facility under Form 3CK, the company files annual Form 3CLA with audited R&D expenditure, and DSIR quantifies the allowable amount on Form 3CL. Eligibility carve-outs are strict — land, building, marketed-product clinical trials, and outsourced research sit outside. Reconciliation against the books of accounts is where most claims leak.